MMIT Launches Indication Briefs for 18 Therapeutic Areas

Understanding a therapeutic area can be challenging, and more so because the health care ecosystem is constantly evolving. Payers are continually seeking innovative ways to contain costs on drug spend, regulators are implementing strategies to better control the pharma industry, and prescribers are facing administrative burdens associated with getting a patient on therapy — all while new and innovative treatments are coming to market.

MMIT’s Indication Briefs, one of our newest products, are intended to provide an in-depth view into a single therapeutic area to help users get up to speed quickly. Each 12- to 15-page report focuses on a specific indication, offering a comprehensive narrative summary alongside data-rich charts showing MMIT’s market research findings. The Indication Briefs are sourced from MMIT’s industry leading Biologics and Oncology Indices powered by the largest payer and integrated delivery system panels in the space. The reports are written by AIS Health journalists using the most recent market research available.

Each report covers key dynamics within a therapeutic area, including treatment options, preferential contracting, first- and second-line preferences, biosimilars, utilization management, administrative burden, manufacturer ratings and patient concerns.

The reports cover:

Oncology Indications:

  • Bladder cancer
  • Breast cancer
  • Colorectal cancer
  • CAR-T therapies
  • Metastatic melanoma
  • Multiple myeloma
  • Non-small cell lung cancer
  • Non-Hodgkin’s lymphoma
  • Prostate cancer
  • Renal cell carcinoma
  • Non-oncology Indications:
  • Atopic dermatitis
  • Diabetes
  • Migraine
  • Multiple sclerosis
  • Orphan diseases
  • Psoriasis
  • Rheumatoid arthritisSeizures

Visit to learn more about Indication Briefs.

AIS Health Staff

Related Posts
November 18

FDA Grants Interchangeable Status to Humira Biosimilar, but Certain Factors May Hamper Its, Other Adalimumabs’ Uptake

Read More
November 18

Oncologists Show Interest in Prescribing New CML STAMP Inhibitor Scemblix

Read More
November 18

Eli Lilly Pounces on Flailing Aduhelm With Competing Drug

Read More


Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today